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In HIV-1/HCV-coinfected patients, chronic HCV infection leads to an increased T-lymphocyte immune 
activation compared to HIV-monoinfected patients, thereby likely contributing to increase HIV-1 
reservoir that is the major barrier for its eradication. Our objective was to evaluate the influence of HCV 
coinfection in HIV-1 viral reservoir size in resting (r) CD4+ T-cells (CD25-CD69-HLADR-). Multicenter 
cross-sectional study of 97 cART-treated HIV-1 patients, including 36 patients with HIV and HCV-
chronic co-infection without anti-HCV treatment, 32 HIV patients with HCV spontaneous clearance 
and 29 HIV-monoinfected patients. rCD4+ T-cells were isolated and total DNA was extracted. HIV 
viral reservoir was measured by Alu-LTR qPCR. Differences between groups were calculated with a 
generalized linear model. Overall, 63.9% were men, median age of 41 years and Caucasian. Median 
CD4+ and CD8+ T-lymphocytes were 725 and 858 cells/mm3, respectively. CD4+ T nadir cells was 305 
cells/mm3. Proviral HIV-1 DNA size was significantly increased in chronic HIV/HCV-coinfected compared 
to HIV-monoinfected patients (206.21 ± 47.38 vs. 87.34 ± 22.46, respectively; P = 0.009), as well as 
in spontaneously clarified HCV co-infected patients when compared to HIV-monoinfected individuals 
(136.20 ± 33.20; P = 0.009). HIV-1/HCV co-infected patients showed a larger HIV-1 reservoir size in 
comparison to HIV-monoinfected individuals. This increase could lead to a greater complexity in the 
elimination of HIV-1 reservoir in HIV-1/HCV-coinfected individuals, which should be considered in the 
current strategies for the elimination of HIV-1 reservoir.
The human immunodeficiency virus (HIV-1) affects 36.9 million people worldwide accordingly to WHO-AIDS1. 
The combined antiretroviral therapy (cART) can successfully suppress HIV-1 viremia and significantly delays the 
progression of the disease2. However, the infection remains currently incurable and lifetime treatment is required 
due to the viral persistence in latent reservoirs that are not accessible to cART and not detectable by the immune 
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system3,4. During HIV-1 replication, the viral genome is stably integrated in the host cell genome but viral genes 
are not expressed at significant levels in resting cells due to the absence of cellular transcription factors. This 
long-life latent reservoir is established in vivo very early after infection5 and consists mainly of several populations 
of memory resting (r) CD4 T-cells including stem central memory (TSCM), central memory (TCM), effector mem-
ory (TEM) and transitional memory (TTM) cells6,7. Once the infected cells become activated, the viral production 
starts4,7. The reservoir size is very small in patients on cART, estimated as 10–100 replication-competent latent 
provirus per million rCD4 T-cells8. However, it is sufficient to refuel viral replication after cART interruption9. 
Viral reservoir is also very stable and does not fade with time even with constant cART10.
Hepatitis C virus (HCV) infection is also a major health problem with 71 million people chronically infected11. 
Although HCV is primarily a hepatotropic virus, chronic HCV infection presents other important extrahepatic 
sites for propagation, including peripheral blood mononuclear cells (PBMCs). As CD4+ T cells are the primary 
site for HIV-1 replication, the co-infection of the same cell could lead to a complex interaction between both 
viruses12–15.
Due to shared routes of transmission, HCV co-infection in people living with HIV-1 affects up to 
6.2% of HIV-infected individuals16. Spontaneous HCV clearance occurs in 10–15% of acute infections in 
HCV-monoinfected individuals but only in less than 10% of HIV-1 infected patients17. A better understanding 
of the impact of HCV infection on HIV-infected patients is essential to adequately manage HIV/HCV coinfected 
patients. In fact, important differences arise from HIV-monoinfected individuals from those co-infected with 
other pathogens, such as the high levels of immune activation and premature immune senescence that occur 
in patients co-infected with cytomegalovirus (CMV)18–21, herpesviruses22, Mycobacterium tuberculosis (TB)23 or 
with HCV24. In HIV/HCV coinfection, this may be due to the enhanced IL-10 production that occurs after HCV 
infection25. Interestingly, coinfection of HIV-1 with other viruses that induce immune activation, such as CMV, 
increases the size of the viral reservoir during the first steps of HIV-1 infection26. But this remains uncertain in 
the case of patients co-infected with HCV.
Consequently, in this work we analyzed the effect of HCV infection in the size of HIV-1 reservoir using 
rCD4+ T cells isolated from treatment-naive HCV co-infected individuals on cART.
Results
Study Patients. Patients were categorized according to their HCV status. In HIV+ monoinfected group, 
patients had never been in contact with HCV. The HIV+/HCV− group was formed with HIV+ patients who 
had been exposed to HCV but experienced HCV spontaneous viral clearance during the first 6 months after 
HCV infection. Finally, the HIV+/HCV+ group was constituted by patients with HIV on cART and active HCV-
chronic infection naïve to any HCV treatment.
Epidemiological and clinical characteristics are summarized in Table 1. Patients were Caucasian, with a 
median age of 50 years [Interquartile range (IQR): 45–54] and 63.9% (n = 62) were men. The median HIV-1 infec-
tion time was 19.9 years (IQR: 8.8–26.6); significantly shorter in HIV+ individuals (15.1 years) than in HIV+/
HVC− (21.7 years) or chronic HIV+/HVC+ (22.8 years) (P = 0.035). Patients with CDC category C status were 
almost one-fourth of the study group (23.7%), being less represented in HIV+ individuals (13.8%) than in HIV+/
HVC− (28.1%) or chronic HIV+/HVC+ (27.8%), but this difference was not statistically significant. All patients 
presented a Fiebig stage ≥ V when initiated cART. Most of the patients who spontaneously cleared HCV or those 
with chronic HIV+/HCV+ acquired HIV-1 through intravenous drug use [62.5% (n = 20) and 58.3% (n = 21), 
respectively]. By contrast, none of HIV-monoinfected patients acquired HIV infection through parenteral route 
(P = 0.017). Thirty-seven percent of the patients were receiving a cART regimen based on integrase inhibitors and 
31% on NNRTIs. More than 20% of patients were receiving dual or monotherapy based on protease inhibitors. 
Coinfection with CMV was also studied in all patients groups, observing a prevalence of 27.6%,46.9% and 44.4% 
in HIV-monoinfected, HIV+/HCV− and HIV+/HCV+ patients, respectively.
Table 2 show the description on cell subpopulations. Median CD4 counts were similar among groups [952 
cells/mm3 (747–1267) for HIV+ , 813 cells/mm3 (701–1005) for HIV+/HCV− and 757 cells/mm3 (524–1063) for 
HIV+/HVC+ subjects, P = 0.531]. No differences were either observed in CD8+ T lymphocytes [845 cells/mm3 
(680–893) for HIV+ , 957 cells/mm3 (714–1219) HIV+/HCV− and 814 (638–1211) HIV+/HVC+ subjects, 
respectively, P = 0.541]. In addition, a tendency to a higher CD4:CD8 ratio was observed in HIV+ subjects [1.2 
(1.1–1.4)] compared to patients exposed to HCV infection [0.8 (0.7–1.1) and 0.9 (0.7–1.1), for HIV+ HCV− and 
HIV+ HIV+ groups, respectively; (P = 0.096). Median CD4+ T nadir cells was 305 (IQR: 268–462) cells/mm3, 
and patients with spontaneous clearance showed the lowest nadir of CD4+ T-cells (P = 0.018) (Table 2).
Table 3 show clinical characteristics related to HCV infection. In HIV+/HCV+ group, the most prevalent 
HCV genotypes were 1 (52.7%, n = 19) and 4 (30.3%, n = 11). Differences in fibrosis stages were significant 
between HIV/HCV groups (P = 0.033). Liver fibrosis, was determined by Fibroscan, in all patients ever in con-
tact with HCV, such as the spontaneous clarifiers (SC) (n = 19) and HIV+/HCV+ (n = 26) co-infected patients. 
IFNL3 (IL28B) (rs12979860) CC genotype was found in 75% (n = 24) of HIV+/HCV− patients, 55.2% (n = 16) 
in HIV-monoinfected individuals and in 37.1% (n = 13) of co-infected patients (P = 0.012).
HIV-1 proviral integration. Mean of proviral HIV-1 DNA copies/106 in rCD4+ T cells was 87.34 ± 22.36 
copies in HIV+ patients, 206.21 ± 47.38 copies in HIV+/HCV+ patients and 136.20 ± 33.20 copies HIV-1 in 
HIV+/HCV− patients (Fig. 1). In HIV+/HCV+ coinfected patients, a 2.3-fold increase in proviral HIV-1 DNA 
copies was observed as compared to HIV-monoinfected group (P = 0.013). This difference remains statistically 
significant (P = 0.009) in the multivariate analysis, adjusting by age, gender, total and nadir CD4 cells, transmis-
sion route and time of infection (Fig. 1 and Table 4). In HIV+/HCV− patients, the univariate model showed a 
tendency to increase in the copies number of proviral HIV-DNA (1.6-fold) although it did not show statistical 
significance (p = 0.209). However, when multivariate analysis was performed, adjusting by gender (male), total 
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nadir CD4, time of HIV infection and transmission route, a statistically significant increase was observed in 
proviral HIV-DNA copies in HIV+/HCV− subjects as compared to the HIV-monoinfected group (P = 0.009) 
(Fig. 1 and Table 4).
Associations between HIV-1 DNA provirus in rCD4 T-cells and the epidemiological and clinical 
characteristics in the different patients groups. Finally, we investigated correlations between the num-
ber of copies of HIV-1 DNA provirus in rCD4 T-cells and the epidemiological and clinical data in the different 
group of patients.
In HIV-monoinfected individuals, a negative correlation was observed between proviral load and the infec-
tion time (SF1), (ρ = −0.506, p = 0.06), whereas a positive correlation between proviral load and male sex 
(ρ = 0.408, p = 0.028) was identified. In HIV+/HCV− group, proviral load was associated to the HIV clinical 
stage (CDC category) (ρ = 0.354, p = 0.47). In HIV+/HCV+ coinfected patients, a negative correlation was found 
between proviral load and CD4% (ρ = −0.365, p = 0.031), and also between provirus vs nadir CD4% (ρ = −0.583, 
p = 0.005) (SF2).
Total (n = 97) HIV+ (n = 29) HIV+/HCV−(n = 32) HIV+/HCV+ (n = 36) P
Median Age, years [median (IQR)] 50 (45–54) 48 (38–54) 52 (48–55) 52 (44–54) 0.372
Weight, kg [median (IQR)] 70 (61–80) 75 (67–84) 76 (64–83) 62 (55–73) 0.002*
Height, cm [median (IQR)] 168 (162–174) 168 (163–173) 169 (164–175) 167 (160–174) 0.512
BMI, kg/m2 [median (IQR)] 24 (22–27) 26 (23–28) 25 (22–28) 23 (21–25) 0.012**
Male, n (%) 62 (63.9) 18 (62.1) 21 (65.6) 23 (63.9) 0.959










Transmission route, n (%)
IDUs 41 (42.3) 0 20 (62.5) 21 (58.3) 0.017
MSM 27 (27.8) 13 (44.8) 6 (18.8) 8 (22.2)
MSW 17 (17.5) 12 (41.4) 3 (9.4) 2 (5.5)
Others 12 (12.3) 3 (9.4) 3 (9.4) 5 (14.1)
CDC category, n (%)
A 51 (52.5) 18 (62.1) 16 (50.0) 17 (47.2) 0.219
B 19 (19.6) 4 (13.8) 6 (18.8) 9 (25.0)
C 23 (23.7) 4 (13.8) 9 (28.1) 10 (27.8)
Unknown 4 (4.1) 3 (10.3) 1 (3.1) 0
cART regimen, n (%)
NNRTIs 30 (30.9) 8 (27.6) 13 (40.6) 9 (25.0) 0.232
PIs 10 (10.3) 2 (6.9) 4 (12.5) 4 (11.1)
INIs 36 (37.1) 11 (37.9) 11 (34.4) 14 (38.9)
Dual therapy 16 (16.5) 6 (20.7) 4 (12.5) 6 (16.7)
Monotherapy 5 (5.2) 2 (6.9) 0 3 (8.3)
CMV Infection, n, (%)
Yes 39 (40.2) 8 (27.6) 15 (46.9) 16 (44.4) 0.309
No 29 (29.9) 12 (41.4) 6 (18.8) 11 (30.6)
Unknown 29 (29.9) 9 (31.0) 11 (34.4) 9 (25.0)
IFNL3 (IL28B) genotype, n (%)
CC 53 (54.6) 16 (55.2) 24 (75.0%) 13 (37.1) 0.008
Non-CC 43 (44.4) 13 (44.8) 8 (25.0) 22 (61.9)
Table 1. Epidemiological Characteristics of the Study Population. Notes: BMI, body mass index; HIV, human 
immunodeficiency virus; HCV, hepatitis C virus; IDUs, Intravenous Drug Users; MSM, men who have sex with 
men; MSW, men who have sex with women; CDC, Centers for Disease Control and Prevention classification 
system for HIV infection; cART, combined antiretroviral therapy; NRTIs, nucleoside analogue reverse 
transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; 
INIs, integrase inhibitors; CMV, cytomegalovirus; %, percentage; IQR, interquartile range. CC: CC genotype. 
*Comparison of weight between groups performed by Mann-Whitney test: HIV+ group vs. HIV+/HCV+ 
group, P = 0.001; HIV+/HCV− group vs. HIV+/HCV+ group, P = 0.005. **Comparison of BMI between 
groups performed by Mann-Whitney test: HIV+ group vs. HIV+/HCV+ group, P = 004; HIV+/HCV− group 
vs. HIV+/HCV+ group, P = 0.050. ***Comparison of time of HIV infection between groups performed by 
Mann-Whitney test: HIV+ group vs. HIV+/HCV− group, P = 0.021; HIV+ group vs. HIV+/HCV+ group, 
P = 0.026. Patients: ▪ HIV+ group: HIV-monoinfected patients that had never been in contact with HCV 
(negative PCR and HCV antibodies). ▪ HIV+/HCV− group: HIV patients who had been exposed to HCV 
but experienced spontaneous viral clearance during the first 6 months after HCV infection (negative PCR and 
positive HCV antibodies). ▪ HIV+/HCV+ group: patients with HIV and active HCV-chronic infection naïve to 
any HCV treatment (positive PCR and HCV antibodies).
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Finally, no correlations were found between proviral HIV-DNA in rCD4 T-cells and age, ratio CD4:CD8, 
transmission route and the different treatment regimens in any group of patients. No correlation was observed 
either between proviral HIV-DNA and the fibrosis stage in spontaneous clarifiers and HIV/HCV coinfected indi-
viduals (SD2).
Discussion
HIV-1 and HCV infections are major health concerns all over the world. When co-infected, patients show a poor 
prognosis than during HIV-1 monoinfection27. This is particularly important regarding to HIV-1 infection, as this 
virus forms a persistent, long-lived reservoir that cannot be eliminated with current cART. It has been described 
that HIV-1 reservoir can be modulated by co-infection with other viruses such as CMV26 but no information 
is available regarding to the effect of HCV coinfection on the HIV-1 reservoir size, despite the fact that 6.2% of 
HIV-1 infected patients are currently co-infected with HCV16. Therefore, to our knowledge, this is the first study 
that shows how the HIV-1 reservoir size may be modified during the natural history of HCV infection, including 
HCV spontaneous cleared infection and HCV chronic-infected individuals.
We observed that chronic HCV infection was associated with an increased HIV-1 proviral integration in 
cART-treated HIV-1 infected patients. Additionally, HIV-1 infected patients who spontaneously clarified HCV 
showed an association in HIV-1 proviral integration in multivariant analysis. Due to the limited amounts of 
sample available, the frequency of cells harboring replication-competent virus could not be evaluated. However, 
integrated HIV-1 DNA in rCD4+ T cells reflects the size of the replication-competent virus in patients receiving 
ART28,29 and is considered an adequate surrogate marker to evaluate the size of the latent reservoir in clinical 
studies30,31.
Total (n = 97) HIV+ (n = 29) HIV+/HCV−(n = 32) HIV+/HCV+ (n = 36) P
CD4+ T cell count, cells/µL [median (IQR)] 787 (625–1020) 952 (747–1267) 813 (701–1005) 757 (524–1063) 0.531
CD4% [median (IQR)] 37.4 (31.2–43.1) 42.5 (38.4–48.7) 33.5 (30.1–40.5) 34.7 (30.5–43.0) 0.064
CD8 T cell count, cells/µL [median (IQR)] 858 (732–1199) 845 (680–893) 957 (714–1219) 814 (638–1211) 0.541
Nadir CD4, cells/µL [median (IQR)] N = 81239 (134–327) 256 (202–374) 225 (110–266) 234 (81–320) 0.230
Nadir CD4% [median (IQR)] N = 5519.0 (12.0–28.1) 25.5 (18.0–28.8) 14.0 (7.0–19.5) 22.0 (14.0–32.0) 0.003*
CD8% [median (IQR)] 38.7 (36.7–43.0) 35.0 (26.5–38.2) 39.0 (32.1–43.1) 40.6 (36.5–43.2) 0.306
CD4:CD8 Ratio 0.9 (0.7–1.1) 1.2 (1.1–1.4) 0.8 (0.7–1.1) 0.9 (0.7–1.1) 0.096
Table 2. Clinical Characteristics of the Study Population. Notes: HIV, human immunodeficiency virus; HCV, 
hepatitis C virus; %, percentage; IQR, interquartile range. *Comparison of nadir CD4 (%) between groups 
performed by Mann-Whitney test: HIV+ group vs. HIV+/HCV− group, P = 0.001; HIV+/HCV− group vs. 
HIV+/HCV+ group, P = 0.010. Patients: ▪ HIV+ group: HIV-monoinfected patients that had never been in 
contact with HCV (negative PCR and HCV antibodies). ▪ HIV+/HCV− group: HIV patients who had been 
exposed to HCV but experienced spontaneous viral clearance during the first 6 months after HCV infection 
(negative PCR and positive HCV antibodies). ▪ HIV+/HCV+ group: patients with HIV and active HCV-
chronic infection naïve to any HCV treatment (positive PCR and HCV antibodies).
Total (n = 68) HIV+/HCV−(n = 32) HIV+/HCV+ (n = 36) P
HCV genotype, n (%)
GT1 19 (52.7) — 19 (52.7) —
GT2 1 (0.03) — 1 (0.03) —
GT3 2 (0.05) — 2 (0.05) —
GT4 11 (30.3) — 11 (30.3) —
Unknown 3 (0.08) — 3 (0.08) —
Fibrosis, n (%)
F0 4 (11.9) 2 (6.3) 2 (5.6) 0.033
F1 (<6kPA) 41 (119.8) 17 (53.1) 24 (66.7)
F2 (6–9kPa) 4 (11.1) 0 4 (11.1)
F3 (>9–12kPa) 3 (8.3) 0 3 (8.3)
F4 (>12kPa) 2 (5.6) 0 2 (5.6)
Unknown 14 (43.4) 13 (40.6) 1 (2.8)
Table 3. Clinical characteristics related to HCV-infected patients. Notes: HIV, human immunodeficiency virus; 
HCV, hepatitis C virus; %, percentage; kPa: kilopascals. Patients: ▪ HIV+/HCV− group: HIV patients who 
had been exposed to HCV but experienced spontaneous viral clearance during the first 6 months after HCV 
infection (negative PCR and positive HCV antibodies). ▪ HIV+/HCV+ group: patients with HIV and active 
HCV-chronic infection naïve to any HCV treatment (positive PCR and HCV antibodies).
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Previous studies have shown that HIV-1 cell-associated RNA transcription and HIV-1 DNA integration are 
reduced in HIV/HCV co-infected patients undergoing therapy with IFN-α and ribavirin32–34. The mechanism by 
which this occurs includes increased levels of the restriction factor TRIM22 induced by IFN-α32 and improved 
cytotoxic function of natural killer cells34. Therefore, we analyzed the effect of HCV co-infection on HIV-1 provi-
ral DNA in patients who had not received previous HCV therapy and had started cART in the same Fiebig stage 
(Phase V). This patient selection represented the interaction between HIV-1 and HCV during the natural evolu-
tion of HVC infection, in patients with spontaneous HCV clearance or with HCV chronic infection.
HIV-1 reservoir is very stable and remains constant despite the effective cART3,10. Maintenance and replen-
ishment of HIV-1 latently infected cells occurs through several mechanisms such as cellular activation and clonal 
and homeostatic expansion that may be relevant in the eventuality of coinfection4,35. In fact, it has been described 
that immune activation induced after co-infection with pathogens such as Mycobacterium tuberculosis enhances 
HIV-1 progression by increasing the number of activated CD4+ T cells36,37. This is due to HIV-1 may infect 
both resting and activated CD4+ T cells but only replicates in activated cells4. Cellular activation may also be 
Figure 1. HIV-1 DNA proviral integration. Integrated HIV-DNA in resting CD4+ (CD4 + CD25-CD69-
HLA-DR-) T lymphocytes from study patients. Integrated HIV DNA was quantified by q-PCR in cross-
sectional samples from different groups of patients: (1) HIV+ group: HIV-monoinfected patients that had 
never been in contact with HCV (negative PCR and HCV antibodies); (2) HIV+/HCV− group: HIV patients 
who had been exposed to HCV but experienced spontaneous viral clearance during the first 6 months after 
HCV infection (negative PCR and positive HCV antibodies); (3) HIV+/HCV+ group: patients with HIV and 
active HCV-chronic infection naïve to any HCV treatment (positive PCR and HCV antibodies). All patients 
were under successfully cART. Molecular forms of HIV were amplified by quadruplicated and values are 
means ± standard error of the mean (SEM). Generalized linear models (GLM) and gamma distribution (log-
link) were used to evaluate differences of number of copies of integrated HIV-DNA among study groups. These 
models were adjusted by main clinical and epidemiological variables (see Materials and Methods). Numbers on 





ARM (95% CI) P
Multivariate analysis 
aAMR (95% CI) P
HIV+ 87.34 ± 22.36 0 — 0 —
HIV+/HCV− 136.20 ± 33.20 1.559 (0.780; 3.118) 0.209 2.514 (1.259; 5.022) 0.009
HIV+/HCV+ 206.21 ± 47.38 2.361 (1.203; 4.634) 0.013 2.659 (1.273; 5.554) 0.009
Table 4. Linear regression analysis by generalized linear model (GLM): (A) Univariate and (B) multivariate 
(adjusted) analysis. Differences of the number of copies of integrated HIV-DNA among study groups were 
evaluated. Note: (a) Univariate analysis comparing HIV-1 DNA provirus vs HIV+/HCV− group or HIV+/
HCV+ groups respectively. (b) Multivariate analysis comparing HIV-1 DNA provirus vs HIV+/HCV− group 
or HIV+/HCV+ groups respectively after adjustment by adjusted by age, gender, total CD4+ T cells, nadir 
CD4+ T cells, transmission route and time of infection. SEM: standard error of the mean; 95%CI: Confidence 
Interval; ARM: Arithmetic mean ratio; aARM: Adjusted arithmetic mean ratio. Patients: ▪ HIV+ group: HIV-
monoinfected patients that had never been in contact with HCV (negative PCR and HCV antibodies). ▪ HIV+/
HCV− group: HIV patients who had been exposed to HCV but experienced spontaneous viral clearance during 
the first 6 months after HCV infection (negative PCR and positive HCV antibodies). ▪ HIV+/HCV+ group: 
patients with HIV and active HCV-chronic infection naïve to any HCV treatment (positive PCR and HCV 
antibodies).
6Scientific RepoRts |          (2019) 9:5606  | https://doi.org/10.1038/s41598-019-41788-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
responsible for the persistent ongoing viral replication that contributes to maintain the reservoir due to subopti-
mal drug concentrations in lymphoid organs38. Consequently, T cell activation due to persistent HCV replication 
observed in HCV chronic co-infected patients may likely account for the higher HIV-1 integration observed in 
these patients. The higher number of intravenous drug users (IDU) enrolled in the groups exposed to HCV may 
also explain part of these differences. There is an immunostimulatory effect on IDU in HCV chronic infected 
patients39 that may lead to systemic immune activation, making impact on HIV-1 integration. Additionally, clear-
ance of HIV-1 replicating cells after viral reactivation relies on host cytotoxic immune responses that become 
dysfunctional and exhausted after long exposure to persistent antigenic stimulation, which is more prevalent in 
HCV chronic patients40.
HCV has also been described to infect lymphoid cells with higher frequency in HIV-1 infected patients41. 
The biological significance of lymphotropic HCV has not been fully elucidated yet and is generally assumed that 
co-infection of HIV-1 latently infected cells, although possible, would be extremely rare due to the low size of 
HIV-1 reservoir8. However, this event may influence on the persistence of HIV-1 reservoir due to HCV may acti-
vate the transcription factor NFAT (nuclear factor of activated T-cells) and induce the expression of IL-242,43 and 
IL-744, being both cytokines involved in homeostatic proliferation that contributes to reservoir replenishment45. 
HIV-1 infected cells also proliferate due to clonal expansion46,47 but the influence of HCV on this mechanism has 
not been described yet. Further studies would be required to solve the relative contribution of homeostatic and 
clonal expansion in HIV-1 reservoir persistence during HIV-1/HCV co-infection.
We demonstrated that chronic HCV infection may influence on HIV-1 proviral integration. In accordance 
to our findings, co-infection with other viruses such as CMV also increased HIV-1 DNA levels and presuma-
bly reservoir seeding in cART-naïve HIV-1 patients26. Co-infection of HIV-1 and CMV shares other similarity 
with HIV-1 and HCV such as that CD4:CD8 ratio was significantly reduced in HIV-1/CMV coinfected subjects 
in comparison to HIV-infected CMV-seronegative individuals20. Accordingly, we observed that CD4:CD8 ratio 
also decreased in HIV-1/HCV coinfected patients. Altogether, these data supported that co-infection with other 
pathogens during HIV-1 disease may increase the reservoir size and affect the disease progression. Despite sub-
jacent molecular mechanisms remain to be elucidated, this should be considered during the management of 
sexual transmitted diseases frequently concurring in HIV-1 infected patients. Moreover, recent studies suggested 
that viral latency is not limited to resting and quiescent CD4+ T cells but that activated and proliferating cells 
may also contribute to the reservoir48,49. Therefore, the number and type of CD4+ T cells able to support viral 
latency may be larger than initially assumed. Further studies in these activated cell populations of HIV-1/HCV 
co-infected patients would seem necessary to ensure that the reservoir is not underestimated, since its depletion 
is the ultimate goal in HIV cure.
In conclusion, we demonstrated that the reservoir of proviral HIV-1 is enhanced in patients also exposed to 
HCV in comparison to HIV-monoinfected individuals. This would mean that the elimination of HIV-1 reservoir 
in HIV/HCV-coinfected individuals could be even more complex.
Methods
Patients. Cross-sectional study of 97 European HIV-1 infected adults receiving suppressive cART for at least 
one year. Patients were enrolled in five tertiary hospitals from the Madrid region (Spain) (SD1). Samples were 
collected between November 2016 and June 2017. All patients had been undetectable for HIV during the previous 
year and had CD4+ T-cells ≥500 cells/mm3 since at least one year before sample collection. Exclusion criteria 
for patient selection were pregnancy, hepatic decompensation, liver damage due to alcohol intake, presence of 
viral hepatitis B antigens or antibodies against viral hepatitis B, opportunistic infections, substance abuse, other 
diseases: diabetes, nephropathies, autoimmune diseases, hemochromatosis, cryoglobulinemia, primary biliary 
cirrhosis, Wilson’s disease, deficiency of alpha1 antitrypsin and neoplasia. Evaluation of liver fibrosis was per-
formed by transient elastography (TE) (FibroScan-502® (Echosens, Paris) using the following cut-off values for 
fibrosis of kPa to identify the different stages of fibrosis: F0-F1 (<6kPA), F2 (6–9kPa), F3 (>9–12kPa) and F4 
(>12kPa)50. IFNL3 rs12979860 single nucleotide polymorphism analysis was performed by qPCR using a custom 
taqman polymorphism assay (Life Technologies, California, USA) for rs12979860. Plasma HCV RNA viral load 
was measured by COBAS® TaqMan® HCV Test v2.0 (Roche Diagnostic Systems Inc., Branchburg, New Jersey, 
USA) and plasma HIV-1 RNA viral load was measured by Amplicor Monitor assay (Roche Diagnostic Systems 
Inc., Branchburg, New Jersey, USA) and real-time NASBA (Easy Mag y Nuclisens Easy Q; BioMerieux, Marcy 
l′Etoile, France) with a detection limit of 20 copies/ml (undetectable viral load).
Age, weight, height, BMI, CDC classification system for HIV infection, cART regimens, CD4 and CD8 T cell 
counts, Nadir CD4 + , HCV genotype, fibrosis status and CMV infection, were obtained from medical records.
Patients were categorized in 3 groups: (1) HIV+ group (n = 29): HIV-monoinfected patients that had never 
been in contact with HCV (negative HCV PCR and HCV antibodies); (2) HIV+/HCV− group (n = 32): HIV 
patients who had been exposed to HCV but experienced spontaneous viral clearance during the first 6 months 
after HCV infection (negative HCV PCR and positive HCV antibodies); (3) HIV+/HCV+ group (n = 36): 
patients with HIV and active HCV-chronic infection naïve to any HCV treatment (positive HCV PCR and HCV 
antibodies). The STROME-ID checklist was used to strength the design and conduct the study51.
Isolation of rCD4+ T cells. Peripheral blood mononuclear cells were extracted from 50 mL of blood and 
rCD4+ T-cells were isolated by negative selection with immunomagnetic beads using EasyStep Human Resting 
CD4+ T Cell Isolation kit (StemCell Technologies). The purity of CD4 + CD25−CD69−HLA/DR−T cells was 
assessed by flow cytometry as >99%.
Quantification of HIV-1 proviral DNA integration. Total DNA from isolated rCD4+ T cells was 
extracted using DNeasy Blood & Tissue kit (Qiagen) and the integrated HIV-DNA was measured by nested 
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Alu–HIV-LTR PCR52. Briefly, Alu-1, Alu-2 and LTR L-M667 primers and Taq DNA polymerase (Roche) were 
used for the first conventional PCR; and LTR AA55M, Lambda T primers and MH603 primers and Taqman 
Universal PCR Master Mix (Promega) for the second quantitative PCR (StepOne, Applied Biosystems). A stand-
ard curve of integrated HIV-DNA from 8E5 cell line using serial dilutions was prepared as reference and CCR5 
was used as housekeeping gene. Values of 2-LTR circle DNA molecules in rCD4+ T cells were subtracted from 
the integrated HIV-DNA value. Primary outcome was the proviral HIV-1 DNA/106 rCD4 T cells. Results were 
given in copy of HIV-1 DNA integrated/rCD4 + cell.
Statistical Analysis. The baseline characteristics of the study population were presented as percentages for 
categorical variables and as medians and interquartile ranges (IQR) for continuous variables. The normalized sta-
tus of the different variables included was verified through the Kolmogorov-Smirnov test. χ2 test and the 2-sided 
Fisher exact test (non-parametric) were used to compare categorical variables. Kruskal-Wallis H test and Mann 
Whitney U test were used to compare continuous variables. Correlation between the variable of interest (proviral 
HIV-1 DNA) and other quantitative variables was analyzed using the Spearman rank correlation test.
Univariate and multivariate analysis with generalized linear models (GLM), gamma distribution (log-link), 
were used to evaluate differences of the number of copies of integrated HIV-DNA among study groups. The 
number of copies are given in mean and standard error of mean (SEM) for each group. This test gives the arith-
metic mean ratio (AMR) or the value by which the arithmetic mean of the primary outcome is multiplied. Each 
multivariate regression test was adjusted by age, gender, total CD4+ T cells, nadir CD4+ T cells, transmission 
route and time of infection. SPSS (v.17; SPSS Inc., Chicago, IL) was used. Statistical significance was defined as 
P < 0.05 (2-tailed).
Ethics. An informed consent was obtained from each subject. Confidentiality and privacy was assured. The 
protocol study was approved by review broads from each institution involved [Comité de Ética de la Investigación 
of Institute of Health Carlos III (Ref: CEI PI67_2015-v4), Comité de Ética de la Investigación of Hospital La Paz 
(Ref: PI-2601), Secretaría Técnica del Comité de Ética de Investigación of Hospital Universitario 12 de Octubre (Ref: 
16/223), Secretaría del Comité de ética de Investigación Médica of Hospital La Princesa (Ref: PI15CIII/00031), 
Comité Ético de Investigación Clínica of Hospital General Universitario Gregorio Marañón (Ref: 09/2016), Comité 
Ético de Investigación con Medicamentos of Hospital Puerta de Hierro (Ref: 20.16)] and developed in accordance 
to the Helsinki Declaration, as revised in 2013.
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